Recent advances of cyclin-dependent kinases as potential therapeutic targets in HR+/HER2− metastatic breast cancer: a focus on ribociclib

References

• MikhailSAlbaneseCPishvaianMJCyclin-dependent kinase inhibitors and the treatment of gastrointestinal cancersAm J Pathol20151851185119725747534
   PubMed Web of Science ®Google Scholar
• BeckJTPotential role for mammalian target of rapamycin inhibitors as first-line therapy in hormone receptor-positive advanced breast cancerOnco Targets Ther201583629363826675495
   PubMed Web of Science ®Google Scholar
• HanahanDWeinbergRAHallmarks of cancer: the next generationCell2011144564667421376230
   PubMed Web of Science ®Google Scholar
• PeyressatreMPrévelCPelleranoMMorrisMCTargeting cyclin-dependent kinases in human cancers: from small molecules to peptide inhibitorsCancers (Basel)20157117923725625291
   PubMed Web of Science ®Google Scholar
• HamiltonEInfanteJRTargeting CDK4/6 in patients with cancerCancer Treat Rev20164512913827017286
   PubMed Web of Science ®Google Scholar
• MalumbresMBarbacidMCell cycle, CDKs and cancer: a changing paradigmNat Rev Cancer20099315316619238148
   PubMed Web of Science ®Google Scholar
• HanahanDWeinbergRAThe hallmarks of cancerCell20001001577010647931
   PubMed Web of Science ®Google Scholar
• Suárez-ArroyoIJLoperena-AlvarezYRosario-AcevedoRMartínez-MontemayorMMGanoderma spp.: a promising adjuvant treatment for breast cancerMedicines (Basel)201741129
   Google Scholar
• OttoTSicinskiPCell cycle proteins as promising targets in cancer therapyNat Rev Cancer20171729311528127048
   PubMed Web of Science ®Google Scholar
• JingYWangGGeYXuMTangSGongZAA-PMe, a novel asiatic acid derivative, induces apoptosis and suppresses proliferation, migration, and invasion of gastric cancer cellsOnco Targets Ther201691605162127073325
   PubMed Web of Science ®Google Scholar
• LaPakKMBurdCEThe molecular balancing act of p16INK4a in cancer and agingMol Cancer Res201412216718324136988
   PubMed Web of Science ®Google Scholar
• SherrCJCancer cell cyclesScience19962745239167216778939849
   PubMed Web of Science ®Google Scholar
• VuHLAplinAETargeting mutant NRAS signaling pathways in melanomaPharmacol Res201610711111626987942
   PubMed Web of Science ®Google Scholar
• FinnRSMartinMRugoHSPalbociclib and letrozole in advanced breast cancerN Engl J Med2016375201925193627959613
   PubMed Web of Science ®Google Scholar
• HortobagyiGNStemmerSMBurrisHARibociclib as first-line therapy for HR-positive, advanced breast cancerN Engl J Med2016375181738174827717303
   PubMed Web of Science ®Google Scholar
• YangCLiZBhattTAcquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependenceOncogene2017362255226427748766
   PubMed Web of Science ®Google Scholar
• RaspéECoulonvalKPitaJMCDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclibEMBO Mol Med2017981052106628566333
   PubMed Web of Science ®Google Scholar
• LefebvreCBachelotTFilleronTMutational profile of metastatic breast cancers: a retrospective analysisPLoS Med201613e100220128027327
   PubMed Web of Science ®Google Scholar
• XuYQinLSunTTwist1 promotes breast cancer invasion and metastasis by silencing Foxa1 expressionOncogene2017361157116627524420
   PubMed Web of Science ®Google Scholar
• WarburtonAJBooneDNInsights from global analyses of long non-coding RNAs in breast cancerCurr Pathobiol Rep201751233428616363
   PubMedGoogle Scholar
• CoronaSPRavelliACretellaDCDK4/6 inhibitors in HER2-positive breast cancerCrit Rev Oncol Hematol201711220821428325261
   PubMed Web of Science ®Google Scholar
• BoérKFulvestrant in advanced breast cancer: evidence to date and place in therapyTher Adv Med Oncol20179746547928717399
   PubMed Web of Science ®Google Scholar
• BrufskyAMDelaying chemotherapy in the treatment of hormone receptor–positive, human epidermal growth factor receptor 2-negative advanced breast cancerClin Med Insights Oncol2015913714726793013
   PubMed Web of Science ®Google Scholar
• MalorniLPiazzaSCianiYA gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancerOncotarget2016742680126802227634906
   PubMed Web of Science ®Google Scholar
• SelliCDixonJMSimsHAAccurate prediction of response to endocrine therapy in breast cancer patients: current and future biomarkersBreast Cancer Res201618111827903276
   PubMed Web of Science ®Google Scholar
• ReinertTBarriosCHOptimal management of hormone receptor positive metastatic breast cancer in 2016Ther Adv Med Oncol20157630432026557899
   PubMed Web of Science ®Google Scholar
• Herrera-AbreuMTPalafoxMAsgharUEarly adaptation and acquired resistance to CDK4/6 inhibition in estrogen receptor-positive breast cancerCancer Res20167682301231327020857
   PubMed Web of Science ®Google Scholar
• SherrCJA new cell-cycle target in cancer — inhibiting cyclin D-dependent kinases 4 and 6N Engl J Med20163752019201923 Perspective27959598
   PubMed Web of Science ®Google Scholar
• RoccaASchironeAMaltoniRProgress with palbociclib in breast cancer: latest evidence and clinical considerationsTher Adv Med Oncol2017928310528203301
   PubMed Web of Science ®Google Scholar
• ParrishKEPokornyJMittapalliRKBakkenKSarkariaJNElmquistWFEfflux transporters at the blood-brain barrier limit delivery and efficacy of cyclin-dependent kinase 4/6 inhibitor palbociclib (PD-0332991) in an orthotopic brain tumor modelJ Pharmacol Exp Ther2015355226427126354993
   PubMed Web of Science ®Google Scholar
• FDA. The U.S. Food and Drug Administration approved ribociclib (KISQALI, Novartis Pharmaceuticals Corp.), a cyclin-dependent kinase 4/6 inhibitor, in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. ID: 4068375. Accessed March 13, 2017.
   Google Scholar
• RubovszkyGHorváthZRecent advances in the neoadjuvant treatment of breast cancerJ Breast Cancer201720211913128690648
   PubMed Web of Science ®Google Scholar
• FDAFDA approves abemaciclib for HR+, HER2− breast cancerCancer Discov Epub2017104
   Google Scholar
• SpringLBardiaAModiSTargeting the cyclin D–cyclin-dependent kinase (CDK)4/6–retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future directionsDiscov Med201621113657426896604
   PubMed Web of Science ®Google Scholar
• KwapiszDCyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclibBreast Cancer Res Treat20171661415428741274
   PubMed Web of Science ®Google Scholar
• AsgharUSBarrARCuttsRSingle-cell dynamics determines response to CDK4/6 inhibition in triple negative breast cancerClin Cancer Res201723185561557228606920
   PubMed Web of Science ®Google Scholar
• GampenriederSPRinnerthalerGGreilRCDK4/6 inhibition in luminal breast cancerMemo20169768127429659
   PubMedGoogle Scholar
• LallemandLDuhouxFPCDK 4/6 inhibitors in the treatment of advanced breast cancerBelg J Med Oncol201711234241
   Google Scholar
• O’LearyBFinnRSTurnerNCTreating cancer with selective CDK4/6 inhibitorsNat Rev Clin Oncol2016137418430
   Web of Science ®Google Scholar
• SuhDHKimMKimKKimHJLeeKKimJWMajor clinical research advances in gynecologic cancer in 2016: 10-year special editionJ Gynecol Oncol2017283e4528382802
   PubMed Web of Science ®Google Scholar
• TossAVenturelliMPeterleCPiacentiniFCascinuSCortesiLMolecular biomarkers for prediction of targeted therapy response in metastatic breast cancer: trick or treat?Int J Mol Sci2017181E8528054957
   PubMed Web of Science ®Google Scholar
• LeeMSHelmsTLFengNEfficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer modelsOncotarget2016726395953960827167191
   PubMed Web of Science ®Google Scholar
• Barroso-SousaRShapiroGITolaneySMClinical development of the CDK4/6 inhibitors ribociclib and abemaciclib in breast cancerBreast Care (Basel)201611316717327493615
   PubMed Web of Science ®Google Scholar
• SpringLMZangardiMLMoyBBardiaAClinical management of potential toxicities and drug interactions related to cyclin-dependent kinase 4/6 inhibitors in breast cancer: practical considerations and recommendationsOncologist20172291039104828706010
   PubMed Web of Science ®Google Scholar
• RaubTJWishartGNKulanthaivelPBrain exposure of two selective dual CDK4 and CDK6 inhibitors and the antitumor activity of CDK4 and CDK6 inhibition in combination with temozolomide in an intracranial glioblastoma xenograftDrug Metab Dispos20154391360137126149830
   PubMed Web of Science ®Google Scholar
• SchröderLBMcDonaldKLCDK4/6 inhibitor PD0332991 in glioblastoma treatment: does it have a future?Front Oncol2015525926649278
   PubMed Web of Science ®Google Scholar
• BartonKLMisuracaKCorderoFPD-0332991, a CDK4/6 inhibitor, significantly prolongs survival in a genetically engineered mouse model of brainstem gliomaPLoS One2013810e7763924098593
   PubMed Web of Science ®Google Scholar
• MichaudKSolomonDAOermannEPharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenograftsCancer Res20107083228323820354191
   PubMed Web of Science ®Google Scholar
• IBRANCE^® (palbociclib) capsules [prescribing information]New YorkPfizer Inc2015
   Google Scholar
• IBRANCE^® (palbociclib). Fact sheetNew YorkPfizer Inc2015
   Google Scholar
• EMAAnnex 1: summary of product characteristicsEuropean Medicines Agency2015
   Google Scholar
• BeaverJAAmiri-KordestaniLCharlabRFDA approval: palbociclib for the treatment of postmenopausal patients with estrogen receptor–positive, HER2-negative metastatic breast cancerClin Cancer Res201521214760476626324739
   PubMed Web of Science ®Google Scholar
• DicklerMNTolaneySMRugoHSMONARCH 1, a Phase 2 study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+/HER2− metastatic breast cancerClin Cancer Res201723175218522428533223
   PubMed Web of Science ®Google Scholar
• KondoSYamamotoNTamuraKPhase 1 study of abemaciclib, a CDK 4 and 6 inhibitor, as a single agent for Japanese patients with advanced cancerEur J Cancer201551Suppl 3S59
   Web of Science ®Google Scholar
• Eli Lilly and CompanyLilly Announces Phase 3 MONARCH 2 Breast Cancer Study of Abemaciclib Met Primary Endpoint of Progression-Free Survival Available from https://investor.lilly.com/releasedetail.cfm?ReleaseID=1017952Accessed August 16, 2017
   Google Scholar
• Eli Lilly and CompanyLilly Builds Upon Body of Data for Abemaciclib with Phase 3 MONARCH 2 Data Demonstrating Superior Progression-Free Survival in Advanced Breast Cancer Available from https://www.newswire.com/news/lilly-builds-upon-body-of-data-for-abemaciclib-with-phase-3-monarch-2-dataAccessed August 16, 2017
   Google Scholar
• SledgeGWJrToiMNevenPMONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2− advanced breast cancer who had progressed while receiving endocrine therapyJ Clin Oncol201735252875288428580882
   PubMed Web of Science ®Google Scholar
• KISQALI^® (ribociclib) tablets [prescribing information]East Hanover, NJNovartis Pharmaceuticals Corporation2017
   Google Scholar
• ChoyMPharmaceutical approval updateP T201742636637128579722
   PubMedGoogle Scholar
• CuriglianoGGómez PardoPMeric-BernstamFRibociclib plus letrozole in early breast cancer: a presurgical, window-of-opportunity studyBreast20162819119827336726
   PubMed Web of Science ®Google Scholar
• CareyLAPerouCMPalbociclib — taking breast-cancer cells out of gearN Engl J Med2015373327327426176385
   PubMed Web of Science ®Google Scholar
• TurnerNCRoJAndréFPALOMA3 Study GroupPalbociclib in hormone-receptor-positive advanced breast cancerN Engl J Med2015373320921926030518
   PubMed Web of Science ®Google Scholar
• TurnerNCHuang BartlettCCristofanilliMPalbociclib in hormone-receptor–positive advanced breast cancerN Engl J Med20153731716721673
   PubMed Web of Science ®Google Scholar
• Eli Lilly and CompanyFDA Grants Priority Review for Lilly’s Abemaciclib for the Treatment of Advanced Breast Cancer2017 Available from https://investor.lilly.com/releasedetail.cfm?ReleaseID=1032523Accessed October 18, 2017
   Google Scholar
• WolffACCDK4 and CDK6 inhibition in breast cancer — a new standardN Engl J Med2016375201993199527959592
   PubMed Web of Science ®Google Scholar
• MurphyCGDicklerMNThe role of CDK4/6 inhibition in breast cancerOncologist201520548349025876993
   PubMed Web of Science ®Google Scholar
• TripathyDBardiaASellersWRRibociclib (LEE011): mechanism of action and clinical impact of this selective cyclin-dependent kinase 4/6 inhibitor in various solid tumorsClin Cancer Res201723133251326228351928
   PubMed Web of Science ®Google Scholar
• WoodACKrytskaKRylesHTDual ALK and CDK4/6 inhibition demonstrates synergy against neuroblastomaClin Cancer Res201723112856286827986745
   PubMed Web of Science ®Google Scholar
• RaderJRussellMRHartLSDual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastomaClin Cancer Res201319226173618224045179
   PubMed Web of Science ®Google Scholar
• HartLSRaderJRamanPPreclinical therapeutic synergy of MEK1/2 and CDK4/6 inhibition in neuroblastomaClin Cancer Res20172371785179627729458
   PubMed Web of Science ®Google Scholar
• ZhangYXSicinskaECzaplinskiJTAntiproliferative effects of CDK4/6 inhibition in CDK4-amplified human liposarcoma in vitro and in vivoMol Cancer Ther20141392184219325028469
   PubMed Web of Science ®Google Scholar
• PablaNGibsonAABuegeMMitigation of acute kidney injury by cell-cycle inhibitors that suppress both CDK4/6 and OCT2 functionsProc Natl Acad Sci U S A2015112165231523625848011
   PubMed Web of Science ®Google Scholar
• O’SullivanCCOvercoming endocrine resistance in hormone-receptor positive advanced breast cancer – the emerging role of CDK4/6 inhibitorsInt J Cancer Clin Res201524 pii:029
   Google Scholar
• InfanteJRCassierPAGerecitanoJFA Phase I study of the cyclin-dependent kinase 4/6 inhibitor ribociclib (LEE011) in patients with advanced solid tumors and lymphomasClin Cancer Res201622235696570527542767
   PubMed Web of Science ®Google Scholar
• SonkeGSHartLLCamponeMEfficacy and safety of ribociclib (LEE011) + letrozole in elderly patients with hormone receptor-positive (HR+), HER2-negative (HER2−) advanced breast cancer (ABC) in MONALEESA-2Eur J Cancer201772Suppl 1S1S2
   Web of Science ®Google Scholar
• SyedYYRibociclib: first global approvalDrugs201777779980728417244
   PubMed Web of Science ®Google Scholar
• O’SullivanCCCDK4/6 inhibitors for the treatment of advanced hormone receptor positive breast cancer and beyond: 2016 updateExpert Opin Pharmacother201617121657166727322766
   PubMed Web of Science ®Google Scholar
• GeoergerBBourdeautFDuBoisSGA Phase I study of the CDK4/6 inhibitor ribociclib (LEE011) in pediatric patients with malignant rhabdoid tumors, neuroblastoma, and other solid tumorsClin Cancer Res201723102433244128432176
   PubMed Web of Science ®Google Scholar
• López-TarruellaSJerezYMárquez-RodasIEchavarriaIMartinMRibociclib for the treatment of advanced hormone receptor-positive, HER2-negative breast cancerFuture Oncol201713242137214928758424
   PubMed Web of Science ®Google Scholar